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ABSTRACT
BACKGROUND: A 2005 meta-analysis suggests that lowering intraocular pressure
(lOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) is
beneficial in reducing the risk for visual field loss in the long term.
OBJECTIVE: The aim of this meta-analysis was to compare the efficacy and toler-
ability of travoprost and latanoprost in patients with OAG or OHT.
METHODS: Pertinent studies published from 1996 to 2008 were identified using
systematic searches of major literature databases, including the Cochrane Library,
MEDLINE, EMBASE, and the Chinese Biomedicine Database. Internet searches of
major search engines, professional associations' Web sites, and manufacturers' databases
were also performed. Randomized controlled trials (RCTs) comparing the effects of
travoprost 0.004% and latanoprost 0.005% in patients with OAG or OHT were se-
lected. The primary efficacy measure was the weighted mean difference (WMD) in the
lOP reduction (IOPR). The primary tolerability measure was the relative risk (RR) for
adverse events. The pooled effects were calculated using the random-effects model.
RESULTS: Seventeen studies (1491 patients) were included in the meta-analysis,
4 of which were of poor quality based on Jadad scoring. Travoprost was associated
with significantly greater diurnal mean IOPRs compared with latanoprost at 2 weeks
and 2 months (WMDs [95% CI} mm Hg: 2 weeks, 1A7 [0.33 to 2.62}; 2 months,
0.71 [0.04 to 1.38}); these values were not significant at 1 (0.81 [-0.78 to 2AO}),
3 (0.01 [-0.50 to 0.52}), and 6 months (0.27 [-OAO to 0.95}). When the 4 studies of
low quality were excluded, no significant treatment differences in diurnal IOPR were
found. IOPR measured at 5 PM was significantly greater with travoprost compared
with latanoprost at 2 weeks (WMD [95% CI}, 0.87 mm Hg [OAO to 1.33}); these
values were not significant at 1 (WMD [95% CI}, 0.60 mm Hg [0.00 to 1.20},
2 (0.65 [-0.69 to 1.99}), 3 (0.04 [-0.51 to 0.59}), 6 (0.00 [-0.68 to 0.68}), and
12 months (0.30 [-0.36 to 0.96}). Travoprost was associated with a significantly
greater frequency of hyperemia than was latanoprost (RR = 1.72 [95% CI, 1.33 to 2.23}).
Rates of serious ocular adverse events did not differ significantly between travoprost
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and latanoprost (cystoid macular edema: RR = 0.22 [95% CI, 0.03 to 1.76}; cataract:
RR = 2.29 [95% CI, 0.90 to 5.83}).
CONCLUSIONS: The findings from the present meta-analysis of these 17 RCTs
suggest that there were no significant differences between travoprost and latanoprost
in IOPR in these patients with OHT or OAG. Both agents were generally well tolerated.
(Curr Ther Res Clin Exp. 2009;70:335-350) © 2009 Excerpta Medica Inc.
KEY WORDS: travoprost, latanoprost, intraocular pressure, meta-analysis.
INTRODUCTION
Glaucoma is a common cause of irreversible blindness. Elevated intraocular pressure
(lOP) is a major risk factor for glaucoma. lOP reduction (IOPR) is the primary goal
of treatments for glaucoma and ocular hypertension (OHT).1,2 A newly published
meta-analysis suggests that lowering lOP in patients with OHT or open-angle
glaucoma (OAG) is beneficial in reducing the risk for visual field loss in the long
term. 3
Prostaglandin analogues are lOP-lowering agents commonly used as first-line
treatments of OHT and OAG. 4 Latanoprost, an F2u-prostaglandin analogue, became
commercially available in 1996. It was associated with greater efficacy in the treat-
ment of OHT compared with timolol in a previously published meta-analysis of data
from 17 studies (1491 patients).5 Travoprost is a topical ocular isopropyl ester pro-
drug that is hydrolyzed by esterases in the cornea to the biologically active free acid.
Travoprost is structurally similar to other F2u-prostaglandin analogues and has a greater
affinity for the prostaglandin F receptor than does latanoprost. 6 Three meta-analyses
have assessed the efficacy of prostaglandin analogues such as latanoprost and travo-
prost,7-9 with inconsistent results.
The present meta-analysis compared the efficacy and tolerability of travoprost and
latanoprost in the treatment of OHT and OAG.
MATERIALS AND METHODS
This meta-analysis was conducted according to a predetermined protocol using
standard systematic review techniques, as outlined by the Cochrane Collaboration
(Oxford, United Kingdom).l0
SEARCH STRATEGY
Randomized controlled trials (RCTs), meta-analyses, and systematic reviews
published from 1996 to 2008 that compared the effects of travoprost 0.004% and
latanoprost 0.005% were identified using a systematic search of the Cochrane
Library, MEDLINE, EMBASE, and the Chinese Biomedicine Database. A broad
search strategy combined terms related to drugs (including a MeSH search of exp
prostaglandins f and synthetic*, and a search of the key words travoprost, Travatan,
latanoprost, Xalatan, and prostaglandin*) and diseases (including a MeSH search of
exp glaucoma* and exp ocular hypertension*, and a search of the key words glaucoma
and ocular hypertension). The original search was conducted in December 2007.
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Regular alerts every 3 months were established on MEDLINE and EMBASE to
capture studies published up to December 31, 2008. Searches of the Cochrane
databases were updated regularly, with the last conducted on issue 4, October
2008.
Google and Yahoo! were searched using the terms travoprost and Travatan up to
December 31, 2008. Web sites of professional associations, such as the Association for
Research in Vision and Ophthalmology, the American Academy of Ophthalmology,
the International Glaucoma Association, and the Association of International Glau-
coma Societies, and their associated conference sites were searched for additional in-
formation. Trial registries, including ClinicalTrials.gov and the Chinese Clinical Trial
Registry, were searched for completed and ongoing trials using the terms travoprost
and Travatan. Manufacturers of pharmaceutical agents, including Pfizer Inc. and Al-
con Inc., were also contacted for additional materials.
A manual search was performed G.-W.e. and G.-L.X., independently) by check-
ing the reference lists of original reports and review articles, retrieved through
the electronic searches, to identifY studies not yet included in the computerized
databases.
TRIALS SELECTION
Published and unpublished trials fulfilling the following inclusion criteria were
included in the present meta-analysis: randomized clinical trials with adequate insti-
tutional review board review and consent processes; trials in patients with OHT or
OAG and an elevated lOP (>21 mm Hg) after a washout period; trials that compared
travoprost 0.004% and latanoprost 0.005% administered as monotherapy once daily;
and;;> 1 of the following end point variables: diurnal mean IOPR from baseline and/or
IOPR measured at 9 AM and/or 5 PM. Studies in patients with other types of glaucoma,
such as normal-tension glaucoma and chronic angle-closure glaucoma, were excluded,
as were those involving no patients with glaucoma; any adjunctive therapy, either
topical or systemic, for lowering lOP; medication administered using a nontopical
route; administration of either drug at a dose and/or frequency other than that de-
scribed above; lOP data that could not be extracted; and/or lOP measurements only
within 24 hours after baseline.
After completion of the searches, 2 of the authors G.-W.e. and G.-L.X.) indepen-
dently assessed the titles and abstracts of all obtained reports for a rough judgment of
an article's eligibility. The full-text copies of possibly and definitely relevant trials
were obtained and assessed by the 2 authors independently according to the defini-
tions in the criteria, which were checked by a third author (R.-L.W.). Only trials
meeting the criteria were assessed for methodologic quality. If 2 articles reported on
the same study population (duplicate publication), the article that reported the results
of the last end point was included, and data that could not be obtained from that
publication were obtained from others.
During selection, the authors were masked to the names of the study investigators
and their institutions, journal titles, sources of funding, and acknowledgments, as
well as the financer of the study, if any.
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DATA EXTRACTION
Data were extracted by 2 authors G.-W.e. and G.-L.X.) independently. For each
study and treatment, the following data were extracted: authors; year of publication;
study design, location, and duration; number of patients; and patients' age, sex, race,
type of glaucoma, and lOP measurements. The proportions of patients who withdrew
and/or experienced adverse events (AEs) were recorded. Numeric discrepancies be-
tween the 2 independent data extractions were resolved after discussion.
OUTCOMES MEASURES
Efficacy was assessed using mean (SD) IOPR measurements (diurnal, 9 AM ±
1 hour, and 5 PM ± 1 hour). Unavailable means were calculated according to the
methods described in the Cochrane Handbook for Systematic Reviews of Interventions
(Cochrane Collaboration). 10 When SE was reported, SD was calculated as SE x N 1/2 .
When the difference in means (MD) and their t values (as obtained from a computer
by entering =tinv [P value, Ntreat + N contro1 - 2} into any cell in a spreadsheet [Excel,
Microsoft Corporation, Redmond, California}) were reported, SD was calculated as
MD x r 1 x (N-\reat + N-lcontrol)-1/2. When mean (SD) IOPRs were not available, they
were calculated as follows: IOPR = IOPbaseline - IOPendpoint and SD10PR = (SD\aseline +
SD2 . - SD . x SD . )1/2end POlllt baselllle end POlllt .
Tolerability was assessed by considering the overall rates of withdrawal due to
AEs and the proportions of patients who experienced AEs.
QUALITATIVE ASSESSMENT
Two of the authors G.-W.e. and G.-L.X.) used standard criteria (allocation conceal-
ment, blinding, intent-to-treat [ITT} analysis, and loss to follow-up) to appraise study
quality in duplicate and to assess quantitative quality using the ]adad scoring system,
as follows ll : allocation concealment, coded as adequate (l point), inadequate or unclear
(both, 0 points); masking, coded as double-masked (2 points), single-masked (1 point),
or open label (0 points); ITT analysis, coded as used (l point) or not used or unable to
assess (both, 0 points); and loss to follow-up, coded as reported (l point) or not
reported (0 points). A]adad score <3 = poor quality.
STATISTICAL ANALYSIS
Not all of the trials reported all of the outcomes of interest; therefore, a separate
meta-analysis was conducted for each comparison and outcome. The analysis of effi-
cacy data was stratified by duration of treatment. Statistical analysis was performed
using RevMan version 4.2.6 (Cochrane Collaboration). Outcomes measures were as-
sessed on an ITT basis, with the ITT population comprising all randomized patients
who received :2:1 dose of active treatment and had valid baseline data available. Rela-
tive risk (RR) was estimated for dichotomous outcomes. Weighted mean difference
(WMD) was calculated for continuous outcomes. The pooled effects ofRR and WMD
were combined using a random-effects modeP2 Results were presented with 95%
CIs. P < 0.05 was considered statistically significant. To detect publication biases,
asymmetry in funnel plots was visually examined.
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RESULTS
The flow of the RCTs included in the present analysis is shown in Figure 1. Of the
1333 studies identified in the initial electronic and manual searches, the full text of
33 articles was reviewed. A total of 22 studies met the criteria for inclusion, with
5 duplicate publications. Therefore, 17 RCTs (1491 patients) were included in the
meta-analysis. 13-29
TRIAL CHARACTERISTICS, POPULATIONS, AND QUALITY
RCTs included were conducted in various areas including China, Greece, Italy,
Latin America, Romania, Spain, Turkey, and the United States (Table 1). In all
Reports identified from literature search
(N = 1333)
Excluded (n = 1300)
Not randomized controlled trials (504)
f----- Duplicate citations (453)
No comparison between travoprost and latanoprost (342)
No glaucoma patients (1)
Studies obtained for full paper review
(n = 33)
Excluded (n = 11)
No data on intraocular pressure (4)
f----- No monotherapy (4)
Angle-closure glaucoma (2)
No glaucoma patients (1)
Eligible studies meeting the criteria
(n = 22)
r----- Excluded (n = 5)Duplicate publications (5)
Eligible trials included in final analysis
(n = 17)
Figure 1. Flow diagram showing citations retrieved from literature searches and number
of trials included in the meta-analysis.
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Table I. Methodologic characteristics of randomized controlled trials included in the meta-analysis of the effects of travoprost :t/II
versus latanoprost (17 trials, 1491 patients). :al>
"/II
Diagnosis, no. (%) e
Age, -InNo. of Withdrawals, Mean Sex Race Jadad
:llStudy Design Location Duration Patients No. (%) (Range), y (M/F) (W/NW) POAG XFG Other OHT Score /II
'"/II
Netland et al 13 DB, PG US 12 mo 390 21 (5.4) 64 (22-94) 189/201 273/117 259 (66.4) 1 «1) 4 (1.0) 126 (32.3) 5 l>:a
Cardascia et al14 DB, PG Italy 6 mo 18 7 (38.9) 52 (46-60) 11/7 NA 18 (100) 0 0 0 4
n
:t
Parrish et al15 SB, PG US 3 mo 274 19 (6.9) 66 (26-90) 120/154 155/119 206 (75.2) 1 «1) 3 (1.1) 64 (23.4) 3
Cellini et al16 DB, PG Italy 6 mo 40 0 64 (38-76) NA NA 40 (100) 0 0 0 3
Dubiner et al 17 DB, PG US 2 wk 34 1 (2.9) 59 (36-72) 11/23 22/12 34 (100)* 0 0 0 4
Kong et al18 DB, PG China 1 mo 47 0 51 (19-70) 32/15 0/47 41 (87.2) 0 0 6 (12.8) 3
Arcieri et al 19 SB, PG Brazil 6 mo 32 5 (15.6) 66 16/16 25/7 17 (53.1) 0 15 (46.9) 0 3
Chisel ita et al20 SB, CR Romania 3 mo 38 0 65 NA NA 38 (100) 0 0 0 2
Garcia-Feijoo
et a121 DB, PG Spain 2 wk 62 14 (22.6) 63 28/34 62/0 13 (21.0) 1 (1.6) 0 48 (77.4) 4
Orzalesi et al22 DB, CR Italy 1 mo 44 0 71 26/18 NA 24 (54.5) 0 0 20 (45.5) 4
(continued)
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Table I (continued).
Age Diagnosis, no. (%)
No. of Withdrawals, Mean Sex Race Jadad
Study Design Location Duration Patients No. (%) (Range), y (M/F) (W/NW) POAG XFG Other OHT Score
Parmaksiz et al23 SB, PG Turkey 6 mo 34 6 (17.6) 66 16/18 NA 0 34 (100) 0 0 2
Hepsen and
Ozkaya24 SB, PG Turkey 3 mo 30 0 62 (50-74) 17/13 NA 0 30 (100) 0 0 2
Konstas et a125 SB, CR Greece 2 mo 40 2 (5.0) 71 24/16 40/0 0 40 (100) 0 0 3
Koz et al26 DB, PG Turkey 6 mo 40 1 (2.5) 52 22/18 NA 23 (57.5) 0 0 17 (42.5) 3
Maul et al 27 DB, PG Latin 6 wk 302 12 (4.0) 61 116/186 145/157 204 (67.5) 12 (4.0) 5 (1.7) 81 (26.8) 5
America
Arcieri et al 28 SB, CR Brazil 1 mo 34 2 (5.9) 58.7 (39-76) 14/20 NA 17 (50.0) 0 0 17 (50.0) 3
Yildirim et al29 SB, PG Turkey 8 wk 32 NA 55.4 NA NA 32 (100) 0 0 0 1
M = male; F = female; W = white; NW = nonwhite; POAG = primary open-angle glaucoma; XFG = exfoliative glaucoma; OHT = ocular hypertension;
DB =double blind; PG = parallel group; NA = not available; SB = single blind; CR = crossover.
*Numbers are numbers of patients with open-angle glaucoma, and not reported primary or secondary.
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17 studies, travoprost 0.004% (832 patients) and latanoprost 0.005% (815 patients)
were administered once daily in the evening. The durations of the studies ranged from
2 weeks to 12 months. Withdrawal rates varied from 0% to 39%. Mean age ranged
from 51 to 71 years. Among the 1381 patients for whom data on sex were
available,13-15,17-19,21-28 642 (46.5%) were male and 739 (53.5%) were female.
Among all 1491 patients, 966 (64.8%) had primary OAG, 379 (25.4%) had OHT,
119 (8.0%) had exfoliative glaucoma, and 27 (1.8%) had "other" types of OAG.
Thirteen trials used a parallel design, 13-19,21,23,24,26,27 ,29 while 4 used a crossover
design. 2o ,22,25,28 ]adad scores were 5 (2 trials),13,27 4 (4),14,17,21,22 3 (7),15,16,18,19,25,26,28
2 (3),20,23,24 and 1 (1)29 (Table 1). Allocation concealment was adequate in 6 studies
(35 %),13,14,19,25,27,28 and unclear in 11 (65 %).15-18,20-24,26,29 Participants were blinded
in 6 studies (35%)13,14,21,22,26,27; investigators, in 12 studies (71%)13-15,20-23,25-29;
and outcomes assessors, in 12 studies (71 %).13-15,19-22,25-29 Data were analyzed using
the ITT principle in 6 studies (35%).13,15,17,21,22,27 Funnel plots were considered
qualitatively symmetric (Figure 2), suggesting the absence of publication bias.
EFFICACY
Diurnal Mean Intraocular Pressure Reduction
Diurnal mean IOPRs are shown in Figure 3. IOPR values were significant with both
study drugs. Travoprost was associated with significantly greater diurnal mean IOPRs
compared with latanoprost at 2 weeks and 2 months (WMDs [95% eI} mm Hg:
0 ,,,,,,,,
0.4 ,:
•
0' 0.8 •
,
•:::?: •~ •w 1.2(j)
1.6
-10 -5
WMD (Fixed)
5 10
Figure 2. Funnel plot of studies comparing travoprost with latanoprost on diurnal mean
intraocular pressure reduction. WMD = weighted mean difference (calculated
using a fixed-effects model).
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1.00 (-0.82 to 2.82)
0.50 (-0.31 to 1.31)
1.26 (-0.28 to 2.80)
0.71 (0.04 to 1.38)
13.49
67.76
18.75
100.00•
Travoprost Latanoprost
Mean (SO), Mean (SO), WMO (Random) Weight WMO (Random)
Trial No. mm Hg No. mm Hg 95%CI (%) 95% CI, mm Hg
2 Weeks
Netland et al i3 197 7.47 (3.70) 193 6.77 (3.70) &~ 36.26 0.70 (-0.03 to 1.43)Oubiner et al17 16 10.42 (2.70) 18 7.10 (2.40) 21.72 3.32 (1.59 to 5.05)Kong et al i8 24 8.75 (2.68) 23 7.79 (3.73) 20.09 0.96 (-0.90 to 2.82)
Parmaksiz et al23 18 9.20 (3.10) 16 7.80 (1.90) 21.94 1.40 (-0.31 to 3.11)
Subtotal 255 8.75 250 7.27 100.00 1.47 (0.33 to 2.62)
Test for heterogeneity: X2 = 7.63, df= 3, P = 0.05, [2 = 60.7%
Test for overall effect: z = 2.51, P = 0.01
1 Month
Kong et al i8 24 8.70 (2.95) 23 7.82 (3.34) ~ 30.88 0.88 (-0.92 to 2.68)Orzalesi et al22 44 6.70 (2.80) 44 7.10 (3.20) 38.83 -0.40 (-1.66 to 0.86)Parmaksiz et al23 18 9.40 (2.90) 16 7.10 (2.60) 30.29 2.30 (0.45 to 4.15)Subtotal 86 8.14 83 7.32 100.00 0.81 (-0.78 to 2.40)
Test for heterogeneity: X2 = 5.77, df= 2, P = 0.06, [2 = 65.3%
Test for overall effect: z = 1.00, P = 0.32
2 Months
Parmaksiz et al23 18 8.80 (3.00) 16 7.80 (2.40)
Konstas et al25 40 7.80 (1.80) 40 7.30 (1.90)
Yildirim et al29 15 7.10 (2.80) 17 5.84 (1.28)
Subtotal 73 7.80 73 7.09
Test for heterogeneity: X2 = 0.84, df= 2, P = 0.66, [2 = 0%
Test for overall effect: z = 2.08, P = 0.04
(continued)
Figure 3. Diurnal mean intraocular pressure reduction (mm Hg) comparing travoprost with latanoprost. WMD = weighted mean
difference (calculated using a random-effects model)
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-0.03 (-0.75 to 0.69)
0.80 (-1.34 to 2.94)
1.10 (-0.20 to 2.21)
0.27 (-0.40 to 0.95)
100.00 -0.10 (0.94 to 0.74)
70.50
9.54
19.96
100.00
193 6.97 (4.22)
6 Months
Netland et al i3 197 7.14 (3.65) 193 7.17 (3.65)
Cellini et al i6 20 9.10 (3.46) 20 8.30 (3.46)
Parmaksiz et al23 18 9.30 (2.90) 16 8.20 (1.20)
Subtotal 235 7.76 229 7.48
Test for heterogeneity: X2 = 2.12, df= 2, P = 0.35, [2 = 5.8%
Test for overall effect: z = 0.80, P = 0.42
12 Months
Netland et al i3 197 6.87 (4.22)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.23, P = 0.82
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Travoprost Latanoprost :a/IIz
Mean (SO), Mean (SO), WMO (Random) Weight WMO (Random) -I
-ITrial No. mm Hg No. mm Hg 95%CI (%) 95% CI, mm Hg :t
/II
:a
3 Months l>
"Netland et al i3 197 7.34 (3.74) 193 7.20 (3.74) 36.35 0.14 (-0.60 to 0.88) /IIe
Parrish et al i5 138 6.70 (3.20) 136 7.00 (3.10) 36.08 -0.30 (-1.05 to 0.45) -I
Cellini et al i6 20 9.20 (3.46) 20 8.50 (3.46) 5.46 0.70 (-1.44 to 2.84) n
:ll
Chisel ita et al20 38 4.62 (4.00) 38 5.55 (3.16) 9.31 -0.93 (-2.55 to 0.69) /II
'"Parmaksiz et al23 18 9.40 (3.10) 16 8.00 (1.40) 9.68 1.40 (-0.19 to 2.99) /II
Hepsen and Ozkaya24 15 6.60 (1.94) 15 7.10 (5.29) 3.13 -0.50 (-3.35 to 2.35)
l>
:a
Subtotal 426 7.13 418 7.12 100.00 0.01 (-0.50 to 0.52)
n
:t
Test for heterogeneity: X2 = 5.54, df= 5, P = 0.35, [2 = 9.7%
Test for overall effect: z = 0.05, P = 0.96
-10 -5 o 5 10
Favors
Latanoprost
Favors
Travoprost
Figure 3 (continued). Diurnal mean intraocular pressure reduction (mm Hg) comparing travoprost with latanoprost. WMD =
weighted mean difference (calculated using a random-effects model).
J.-W. CHENG ET AL.
2 weeks, 1.47 [0.33 to 2.62}; 2 months, 0.71 [0.04 to 1.38}); these values were not
significant at 1 (0.81 [-0.78 to 2.40}), 3 (0.01 [-0.50 to 0.52}), and 6 months (0.27
[-0.40 to 0.95}). When the 4 trials of poor quality were excluded,20,23,24,29 no
significant treatment differences in diurnal mean IOPR were found.
9 AM Intraocular Pressure Reduction
Five trials (748 patients) reported the 9 AM mean IOPR at 2 weeks (travoprost,
7.71 mm Hg; latanoprost, 7.58 mm Hg [Table II})13-15,17,19,21; the treatment difference
was nonsignificant (WMD, 0.13 mm Hg [95% CI, -0.33 to 0.58}). Treatment differences
from the trials that reported this outcome at additional time points were also not signifi-
cant (WMDs [95% CI} mm Hg: 1 month, 0.60 [-0.36 to 1.57}; 2 months, 1.31 [-0.58
to 3.19}; 3 months, -0.07 [-0.73 to 0.60}; 6 months, 0.00 [-0.59 to 0.59}; and
12 months, -0.40 [-1.19 to 0.39}).
5 PM Intraocular Pressure Reduction
Three trials (726 patients) reported the 5 PM mean IOPR at 2 weeks (travoprost,
7.72 mm Hg; latanoprost, 6.85 mm Hg)13,17,21; the difference between groups was statis-
tically significant (WMD [95% CI}, 0.87 mm Hg, [0.40 to l.33}) (Table II). The treat-
ment differences were not significant at additional time points (mean WMDs [95 % CI}
mm Hg: 1 month, 0.60 [0.00 to 1.20}; 2 months, 0.65 [-0.69 to 1.99}; 3 months, 0.04
[-0.51 to 0.59}; 6 months, 0.00 [-0.68 to 0.68}; and 12 months, 0.30 [-0.36 to 0.96}).
TOLERABILITY
Across all studies, the AEs reported were usually mild to moderate and resolved
without treatment. The 2 most common AEs were hyperemia (travoprost, 272/644
[42.2%}; latanoprost, 158/624 [25.3%} [pooled RR = 1.72; 95% CI, 1.33 to 2.23}),
and eyelash growth (travoprost, 14/176 [8.0%}; latanoprost, 9/174 [5.2%} [pooled
RR = 1.50; 95% CI, 0.74 to 3.02}) (Table III). Three patients in the travoprost
group discontinued due to conjunctival hyperemia. There were no significant differ-
ences between travoprost and latanoprost in the incidence of any reported AEs, includ-
ing serious ocular AEs (cystoid macular edema, 1/17 [5.9%} vs 4/15 [26.7%} [RR =
0.22; 95% CI, 0.03 to 1.76}; cataract, 14/197 [7.1%} vs 6/193 [3.1%} [RR = 2.29;
95% CI, 0.90 to 5.83}).
DISCUSSION
The findings from the present meta-analysis suggest that travoprost was as effective
as latanoprost in lowering lOP in patients with OHT or OAG, with significantly
greater mean diurnal and 5 PM IOPRs found at 2 weeks.
lOP lowering has been proven to reduce the risk of glaucomatous progression in
patients with glaucoma. A meta-analysis of RCTs revealed that an lOP-lowering
strategy delays the progression of visual field deterioration in patients with OHT or
manifest glaucoma. 30 Depending on the glaucomatous damage and the presence of
other risk factors, the target lOP sometimes has to be chosen such that lOP lowering
beyond 35% is necessary,3l From all the choices of lOP-lowering agents, a reasonable
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Table II. Intraocular pressure reduction (IOPR) with travoprost and latanoprost in patients with open-angle glaucoma or ocular /II:a
hypertension. l>
"/IIe
Travoprost Latanoprost -In
Time of Day/ No. of No. of Mean No. of Mean WMD Test for Test for
:ll
/II
'"Time Point Trials Patients IOPR Patients IOPR (95% GI) Heterogeneity Overall Effect /II
l>
:a
9 AM n:t
2 wk 5 377 7.71 371 7.58 0.13 (-0.33 to 0.58) Q = 2.63; P = 0.62 z = 0.58; P = 0.58
1 mo 5 128 7.31 126 6.70 0.60 (-0.36 to 1.57) Q = 6.51; P = 0.16 z = 1.23; P = 0.22
2 mo 4 81 8.12 81 6.81 1.31 (-0.58 to 3.19) Q = 18.29; P < 0.001 z = 1.36; P = 0.17
3 mo 4 361 7.67 353 7.73 -0.07 (-0.73 to 0.60) Q = 4.34; P = 0.23 z = 0.19; P = 0.85
6 mo 4 243 7.11 237 7.11 0.00 (-0.59 to 0.59) Q = 1.78; P = 0.62 z = 0.01; P = 0.99
12 mo 1 197 7.10 193 7.50 -0.40 (-1.19 to 0.39) NA z = 1.00; P = 0.32
5 PM
2 wk 3 368 7.72 358 6.85 0.87 (0.40 to 1.33) Q = 0.44; P = 0.80 z = 3.65; P < 0.001
1 mo 3 223 7.75 214 7.16 0.60 (0.00 to 1.20) Q = 0.44; P = 0.80 z = 1.95; P = 0.05
2 mo 2 55 6.58 40 5.93 0.65 (-0.69 to 1.99) Q = 1.89; P = 0.17 z = 0.95; P = 0.34
3 mo 2 335 6.55 329 6.51 0.04 (-0.51 to 0.59) Q = 0.03; P = 0.86 z = 0.14; P = 0.89
6 mo 1 197 6.50 193 6.50 0.00 (-0.68 to 0.68) NA z = 0.00; P = 1.00
12 mo 1 197 6.60 193 6.30 0.30 (-0.36 to 0.96) NA z = 0.88; P = 0.38
WMD = weighted mean difference (calculated using a random-effects model); NA = not applicable.
Table III. Tolerability of travoprost and latanoprost in patients with open-angle glaucoma or ocular hypertension.
Crude Event Rate, n/N (%)
No. of Test for Test for
Adverse Event Trials Travoprost Latanoprost RR (95% CI) Heterogeneity Overall Effect
Hyperemia 9 272/644 (42.2) 158/624 (25.3) 1.72 (1.33-2.23) Q = 13.01; P = 0.11 z = 4.16; P < 0.001
Eye pain 5 25/568 (4.4) 12/554 (2.2) 1.93 (0.99-3.78) Q = 2.09; P = 0.72 z = 1.92; P = 0.05
Pruritus 5 27/568 (4.8) 19/554 (3.4) 1.31 (0.74-2.30) Q = 1.71; P = 0.79 z = 0.92; P = 0.36
Headache 4 10/293 (3.4) 7/287 (2.4) 1.36 (0.54-3.43) Q = 1.16; P = 0.76 z = 0.65; P = 0.52
Visual acuity
decrease 4 23/508 (4.5) 18/492 (3.7) 1.14 (0.49-2.63) Q = 3.96; P = 0.27 z = 0.31; P = 0.76
Eye irritation 3 10/216 (4.6) 19/214 (8.9) 0.53 (0.25-1.21) Q = 0.93; P = 0.63 z = 1.67; P = 0.09
Foreign body
sensation 3 22/392 (5.6) 15/380 (3.9) 1.38 (0.69-2.76) Q = 2.23; P = 0.33 z = 0.90; P = 0.37
Keratitis 3 11/269 (4.1) 7/263 (2.7) 1.53 (0.61-3.89) Q = 0.99; P = 0.61 z = 0.90; P = 0.37
Skin or iris
discoloration 3 14/373 (3.8) 18/367 (4.9) 0.75 (0.38-1.51) Q = 1.54; P = 0.46 z = 0.80; P = 0.42
Blepharitis 2 8/237 (3.4) 7/233 (3.0) 1.09 (0.41-2.90) Q = 0.43; P = 0.51 z = 0.17; P = 0.86
Blurred vision 2 8/335 (2.4) 9/329 (2.7) 1.07 (0.19-6.04) Q = 1.57; P = 0.21 z = 0.08; P = 0.93
Dry eye 2 11/335 (3.3) 4/331 (1.2) 2.39 (0.57-10.07) Q = 1.40; P = 0.24 z = 1.18; P = 0.24
Eyelash growth 2 14/176 (8.0) 9/174 (5.2) 1.50 (0.74-3.02) Q = 0.19; P = 0.67 z = 1.12; P = 0.26
Cataract 1 14/197 (7.1) 6/193 (3.1) 2.29 (0.90-5.83) NA z = 1.73; P = 0.08
Conj unctivitis 1 1/16 (6.3) 0/18 3.35 (0.15-76.93) NA z = 0.76; P = 0.45 ~
Cystoid macular ~edema 1 1/17 (5.9) 4/15 (26.7) 0.22 (0.03-1.76) NA z = 1.43; P = 0.15 n
:t
RR = relative risk (calculated using a random-effects model); NA = not applicable.
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initial approach would be to choose a monotherapy that will get the lOP as low as
safely possible in each particular patient. 32 A previously published meta-analysis of
42 articles (9295 patients) reported the IOPRs with bimatoprost (7.81 mm Hg),
travoprost (7.69 mm Hg), and latanoprost (6.69 mm Hg).7 These values were compa-
rable to the WMD IOPRs with travoprost (range, 7.10-9.47 mm Hg) and latanoprost
(range, 7.09-8.23 mm Hg) at various time points in the present analysis. Li et al8 ana-
lyzed data from 12 RCTs (3048 patients) and reported that the efficacy of travoprost
0.004% was similar to that of bimatoprost 0.03% and latanoprost 0.005%. However,
Denis et al9 analyzed data from 9 RCTs (1318 patients) that compared the efficacy of
prostaglandin analogues (eg, travoprost, bimatoprost, and latanoprost) and reported that
travoprost and bimatoprost might be more effective than latanoprost for lOP lowering
in patients with OHT or OAG. In contrast to those analyses, the present meta-analysis
examined RCTs that used direct comparisons between travoprost and latanoprost, and
found that these agents were comparable in lowering lOP.
Both travoprost and latanoprost were generally well tolerated. That conjunctival
hyperemia was significantly more common with travoprost than with latanoprost
might limit its use due to cosmetic concern. However, this AE was mild and resolved
without treatment. 33 ,34 Three patients in the travoprost group discontinued due to
conjunctival hyperemia.
STRENGTHS
Whereas previously published meta-analyses calculated just 1 IOPR and/or used
only 1 postbaseline time point, the present analysis used several IOPR end points
(diurnal, 9 AM, and 5 PM) at 2 weeks and 1,2,3,6, and 12 months. To avoid potential
heterogeneity based on data pooled from trials of different durations, the analyses of
efficacy data were stratified by duration of treatment and each time point was analyzed
separately. To avoid acknowledged and covert duplication of data, 2 independent re-
searchers judged the eligibility of articles and extracted data from the eligible articles,
with discrepancies resolved using discussion among all of the authors. Only the series
of the same patient group at the last end point were included in the present analysis.
Asymmetry was explored using funnel plots to detect potential publication biases,
and none was found. To further avoid publication bias, multiple databases and Web
sites were searched, without trial exclusion based on language.
LIMITATIONS
One limitation of the present analysis was that 4 trials included in the analysis were
of poor quality based on ]adad scores. Most of the included trials were of a duration
of < 12 months. Pragmatic RCTs with durations> 12 months are needed to assess the
long-term efficacy of travoprost in lowering lOP.
CONCLUSIONS
The findings from the present meta-analysis of these 17 RCTs suggest that there were
no significant differences between travoprost and latanoprost in IOPR in these pa-
tients with OHT or OAG. Both agents were generally well tolerated.
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